

Schedule 3 – Information on Management Positions

Martin Møller

Chairman of the Board since April 2022, member of the Board of Directors since 2021.

Education: MA in humanities from the University of Copenhagen.

Background: Worked for more than 20 years at the international management consulting firm McKinsey & Company, specializing in healthcare, biotech, pharmaceuticals and life sciences, since 2007 as a Partner and since 2013 as a Senior Partner, until 2021. In that role, he has advised companies globally on strategy, growth and transformations, including drug development and innovation.

Other ongoing assignments: Chairman in Re-Zip ApS, Board member in Immunovia AB and Rehaler A/S.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants: 6.266 shares and 128.542 warrants.

Alejandra Mørk

Member of the Board of Directors in Scandion Oncology A/S since 2022.

Education: PhD and MSc Pharm.

Background: Worked all her career in drug development. First in Nycomed Pharma for 18 years in various leadership positions in Project Management, Clinical Development, Regulatory Affairs and as overall responsible for Drug Development being part of Nycomed top-management. In 2008 Alejandra acquired KLIFO A/S to build an international drug development consultancy supporting biotech and pharma companies to progress and increase value of their product development projects. Alejandra Mørk has since 2011 been member of the Board of Danish Biotech.

Other ongoing assignments: Board member and part time employee in Klifo A/S, board member in Epoqe Pharma ApS and Danish Biotech, and member of the Danish Academy of Technical Sciences.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants: 64.271 warrants.

Keld Flintholm Jørgensen

Member of the Board of Directors in Scandion Oncology A/S since 2022.

Education: BSc in Economics & Business Administration and MSc in Business Economics & Auditing, Copenhagen Business School.

Background: +20 years of experience within the global pharma industry across different functional areas such as Business Development, Corporate Strategy, Finance and Auditing. Served in several finance leadership positions at Roche from 2000 and until 2011, where he joined Roche Strategic Partnering. From 2017 he was promoted to Global Head of Roche Strategic Partnering and a member of the Roche Pharma's Late Stage Portfolio Committee. In 2019, Keld joined Lundbeck as EVP and Chief Business Officer, responsible for Corporate Strategy and Business Development. During the past +10 years in BD, Keld has executed M&A's and partnering deals worth >10 bio USD

Other ongoing assignments: SVP & Chief Business Officer of Lundbeck A/S.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants: 64.271 warrants.

New board members

Per Pfeiffer

Education: MD (Candidate of Medicine) 1982 and PhD 1997, University of Southern Denmark.

Background: Danish Board Authorization in Oncology 1993 (Specialist in Medical Oncology and Radiotherapy). Consultant 1999, professor 2008. He has published more than 280 peer-reviewed articles (H-factor 56) in prestigious journals and he serves as co-editor and reviewer for several oncology journals. He is co-author of ESMO (European) guidelines 2012 and 2016 guidelines in colorectal cancer and ESMO guidelines 2023 in pancreatic cancer. Most recently he planned, presented and published a Danish randomized trial in chemo-refractory metastatic colorectal cancer (Danish Lonsurf trial).

Other ongoing assignments: Professor & consultant in GI-oncology, Dept. of Oncology, OUH & Professor, USD.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants: No shares or warrants.

Michel Ducreux

Education: MD, PhD, Professor of Medical Oncology.

Background: Head of the digestive oncology unit and the digestive cancer group at Gustave Roussy (Cancer Centre in Paris, France) since 1997. Author of more than 540 articles published in indexed journals. Main research topics: management of metastatic colorectal cancer, metastatic pancreatic carcinoma, bile carcinoma, hepatocellular carcinoma and the treatment of neuroendocrine tumors. Various leadership roles in ESMO and EORTC related to gastrointestinal oncology. Participation in more than 300 clinical trials during the last 25 years and Principal Investigator of more than 80 clinical trials during the last 15 years.

Other ongoing assignments: Head of GI oncology Unit, Department of Medical Oncology, Inserm U1279, Team "Endocytosis, Cytoskeleton and Cell Migration" and member of the scientific advisory boards of RenovoRx and Abcely.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants: No shares or warrants.